Avidity Biosciences Inc
RNAM
Classement en actions
#2082
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Prix de l'action
$71.34
Dernière synchronisation: 2026-03-03
Capitalisation boursière
$9.84B
Changement (1 jour)
0.00%
Changement (1 an)
-
Pays
US
Échange Avidity Biosciences Inc (RNAM)
Catégorie
Healthcare
EPS pour Avidity Biosciences Inc (RNAM)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Avidity Biosciences Inc, l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Avidity Biosciences Inc de 2018 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2025 | $-4.97 | 71.97% |
| 2024 | $-2.89 | -0.69% |
| 2023 | $-2.91 | -12.87% |
| 2022 | $-3.34 | 17.19% |
| 2021 | $-2.85 | 39.02% |
| 2020 | $-2.05 | 210.61% |
| 2019 | $-0.66 | 120.00% |
| 2018 | $-0.30 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| $13.70 | - |
BE
|
